Stocklytics Platform
Asset logo for symbol CCCC
C4 Therapeutics
CCCC64
$4.55arrow_drop_down0.43%-$0.01
Penny Stock
Asset logo for symbol CCCC
CCCC64

$4.55

arrow_drop_down0.43%
Key Stats
Open$4.56
Prev. Close$4.55
EPS-1.71
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$321.17M
PE Ratio-
LOWHIGH
Day Range4.47
4.74
52 Week Range1.06
11.88
Ratios
EPS-1.71
Fundamentals
Gross Profit-
Payout Ratio-
Industry average yield2.68%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

CCCC-
US Healthcare Sector-
US Market-
warning

CCCC / Market

CCCC lose to the US Market which returned 273.33% over the last twenty four hours.
warning

CCCC / Healthcare Sector

CCCC lose to the US Healthcare sector which returned 2.64% over the last twenty four hours.

C4 Therapeutics (CCCC) Statistics

Founded in 2015, C4 Therapeutics Inc (CCCC) is a biotechnology company that focuses on developing targeted protein degradation therapies for the treatment of various diseases. The company's proprietary platform, known as Degronimid, enables the selective elimination of disease-causing proteins by targeting them for degradation. This approach has the potential to address a wide range of diseases, including cancer, neurodegenerative disorders, and autoimmune conditions.
C4 Therapeutics Inc has gained significant attention in the biotech industry due to its innovative approach to protein degradation. The company's valuation metrics reflect this interest, with a high market capitalization and a solid enterprise value. This indicates that investors have confidence in the company's potential for growth and success.
add C4 Therapeutics  to watchlist

Keep an eye on C4 Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has C4 Therapeutics (CCCC) stock's performance compared to its sector and the market over the past year?

Over the past year, C4 Therapeutics (CCCC) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 34.19%, C4 Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 66.35%, it has fallen short of the market average. This comparison highlights C4 Therapeutics 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of C4 Therapeutics (CCCC) stock?

The PE ratio for C4 Therapeutics (CCCC) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of C4 Therapeutics (CCCC) stock?

The Earnings Per Share (EPS) for C4 Therapeutics (CCCC), calculated on a diluted basis, is -$1.71. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of C4 Therapeutics (CCCC) stock?

The operating margin for C4 Therapeutics (CCCC) is -183.86%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of C4 Therapeutics (CCCC) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of C4 Therapeutics (CCCC) is -$115.13M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does C4 Therapeutics (CCCC) have?

C4 Therapeutics (CCCC) has a total debt of $67.1M. The net debt, which accounts for cash and cash equivalents against the total debt, is $7.45M.

Take Your Investments to a Whole New Level